Technology Transfer News

Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology.

At the this year’s edition of the TOP 100 Swiss Startup Award, where Switzerland’s best startups are celebrated, Araris ranks TOP11! What a great success for Araris, after positions 13 in 2020 and 95 in 2019. 

We congratulate Philipp Spycher (CEO) and his team for this great achievement!

The innovation campus of Park Innovaare is growing in leaps and bounds. The modern buildings, under construction in the immediate vicinity of PSI, are ideally suited to the R&D needs of industry with office-, laboratory- and clean room space.

Since the ground-breaking ceremony in November 2019, construction work on the 38,000 m2 buildings, led by ERNE AG, has been on schedule and completion is expected at the end of 2023. Then the companies and spin-offs already located in the park, as well as several PSI departments, will move into the new buildings along with other companies wanting to benefit from Park Innovaare's innovation ecosystem.

For further information: https://www.parkinnovaare.ch/switzerland-innovation-hightech-campus-research-park

Circular cities, food and agriculture as well as infrastructure and logistics: this is the focus of the third edition of CE2 on 22 September 2021 at the Kursaal Bern. The conference is the compass for companies that want to anchor sustainable business and the circular economy in their DNA. Renewable energies and recycling are important innovation topics at PSI - this is why we support CE2 as a partner.

Meet other forward-thinkers, designers, and specialists, exchange ideas and get inspired by around 25 experts in keynotes and deep dive sessions. These include Simonetta Sommaruga (Federal Councillor), Thomas Vellacott (CEO, WWF Switzerland), Cllr. Anna Richardson (City Convener, Sustainability and Carbon Reduction, Glasgow City Council), Dr Ian Roberts (CTO, Bühler Group) and Patrick Camele (CEO, SV Group).

Further information and registration at www.ce2.ch/en/

For the last three years, Dr Remo Lütolf, the retiring Chairman of the Board of innovAARE AG in Villigen has successfully guided the development of Park Innovaare. With his background as former country manager of ABB Switzerland, Remo Lütolf was able to incorporate his broad know-how and experience from industry into his mandate for the Park. His successor, Dr Christian Brönnimann, is the founder and CEO of Dectris AG, a company based in Baden-Daettwil. Dectris is the world's number one in the manufacture of X-ray detectors, and is a successful spin-off company of the Paul Scherrer Institute.

In der Reihe "Forschung online erleben" veranstaltet das PSI am Mittwoch, 23. Juni 2021 von 19 bis 21 Uhr  einen virtuellen Vortrag & Rundgang  durch die Krebsbehandlungsanlagen am PSI. Erfahren Sie mehr darüber, welche Krebsarten am Zentrum für Protonentherapie des PSI mit Protonen behandelt werden, welche Patienten für eine solche Therapie infrage kommen und wie eine Behandlung abläuft.

Wählen Sie sich über diesen Link direkt in den Live-Video-Rundgang ein:

Mittwoch, 23. Juni 2021 – 19 bis 21 Uhr

https://psich.zoom.us/j/61021531635 , Meeting-ID: 61021531635

Weiterführende Informationen finden Sie unter folgendem Link:

https://www.psi.ch/de/psiforum/news/forschung-online-erleben-die-protonentherapie-am-psi

The importance of rare earths has increased steadily in recent years - and so has their demand. Digitization and e-mobility in particular heavily rely on rare earth elements. However, Europe is heavily dependent on China in this area, where a large proportion of the current worldwide rare earths supply is sold from.

The PSI-EPFL spin-off REMRETEch is focusing precisely on this and is dedicated to the commercialisation of rare earth recycling. REMRETEch isolates rare earths from electrical scrap with its promising and scalable technology. The start-up has already taken first steps out of the laboratory and is currently working on a pilot project:

Employers complain about a shortage of skilled workers, while young researchers often do not know exactly where to look for their next professional challenge. Strengthening the bridge between academia and industry at PSI can help open up new perspectives for both sides.

Online Symposium on the provision of innovative diagnostic and therapeutic radiopharmaceuticals for a paradigm shift in cancer therapy

The approach of using radioisotopes of the same element for theragnostics has been successfully investigated in previous preclinical studies. The PSIs Tattoos Infrastructure Project will allow the production and subsequent investigation of four interesting “sister” Terbium radionuclides for all modalities in diagnostic and therapeutic nuclear medicine. The virtual Mini Symposium hosted by PSIs specialist will give interested participants the opportunity to listen to and question experts in this emerging field of personalized medicine.

Please find more information on the program and registration for the online symposium:

https://www.psi.ch/de/zrw/tattoos-mini-symposium